Scarica l'app Stockscreener
21.35
7.97%
-1.85
Dopo l'orario di chiusura:
21.35
Precedente Chiudi:
$23.20
Aprire:
$22.14
Volume 24 ore:
1.62M
Relative Volume:
0.88
Capitalizzazione di mercato:
$2.64B
Reddito:
$247.00M
Utile/perdita netta:
$-249.00M
Rapporto P/E:
-6.9094
EPS:
-3.09
Flusso di cassa netto:
$-267.00M
1 W Prestazione:
-10.41%
1M Prestazione:
-17.25%
6M Prestazione:
+151.18%
1 anno Prestazione:
+43.10%
Intervallo 1D:
$20.86
$22.50
Intervallo di 1 settimana:
$20.59
$23.99
Portata 52W:
$6.50
$26.40
Arcus Biosciences Inc Stock (RCUS) Company Profile
Nome
Arcus Biosciences Inc
Settore
Industria
Telefono
(510) 694-6200
Indirizzo
3928 POINT EDEN WAY, HAYWARD, CA
Confronta RCUS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
21.35 | 2.87B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-26 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Iniziato | H.C. Wainwright | Neutral |
| 2024-10-08 | Iniziato | Wells Fargo | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-11-23 | Iniziato | Evercore ISI | Outperform |
| 2020-04-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-09-27 | Iniziato | Mizuho | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2018-10-09 | Iniziato | Wedbush | Outperform |
| 2018-04-09 | Iniziato | Citigroup | Buy |
| 2018-04-09 | Iniziato | Goldman | Neutral |
| 2018-04-09 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
Is Arcus Biosciences Inc. stock a buy for dividend growthWeekly Market Outlook & Smart Allocation Stock Tips - ulpravda.ru
Growth Review: Is Arcus Biosciences Inc. stock a buy for dividend growth2025 Trading Volume Trends & Fast Moving Stock Trade Plans - ulpravda.ru
Can Arcus Biosciences Inc. stock double in next 5 yearsMarket Performance Recap & AI Enhanced Trade Execution Alerts - ulpravda.ru
Arcus Biosciences (RCUS) Downgraded by Morgan Stanley Amid Recen - GuruFocus
Will Arcus Biosciences Inc. stock maintain growth storyJuly 2025 Earnings & Accurate Buy Signal Alerts - ulpravda.ru
Arcus stock downgraded at Morgan Stanley (RCUS:NYSE) - Seeking Alpha
Morgan Stanley Downgrades Arcus Biosciences (RCUS), Adjusts Pric - GuruFocus
Morgan Stanley downgrades Arcus Biosciences stock on balanced risk/reward - Investing.com Canada
Arcus Biosciences (RCUS) Sets Ambitious 2026 Agenda for Casdatif - GuruFocus
Biotech outlines 2026 plans for kidney cancer and atopic dermatitis - Stock Titan
Arcus Biosciences (RCUS) Shares Fall by Over 9% - GuruFocus
Arcus Biosciences (NYSE:RCUS) Trading Down 7.8% Following Insider Selling - MarketBeat
Portfolio Shifts: Is Arcus Biosciences Inc stock a buy for dividend growthLong Setup & AI Powered Buy and Sell Recommendations - moha.gov.vn
Insider Sell: Goeltz II Robert C. Sells Shares of Arcus Bioscien - GuruFocus
Insider Selling: Arcus Biosciences (NYSE:RCUS) CFO Sells 6,552 Shares of Stock - MarketBeat
The Technical Signals Behind (RCUS) That Institutions Follow - Stock Traders Daily
Arcus Biosciences (NYSE:RCUS) Trading Up 2.8%Should You Buy? - MarketBeat
Certain Common Stock of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2025. - marketscreener.com
Certain Stock Optios of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2025. - MarketScreener
Is Arcus Biosciences Inc a good long term investmentDebt-to-Equity Ratio Analysis & AI-Based Predictions Available Free - earlytimes.in
Arcus Biosciences Earnings Notes - Trefis
Understanding Momentum Shifts in (RCUS) - news.stocktradersdaily.com
Can Arcus Biosciences Inc. stock deliver consistent earnings growthQuarterly Investment Review & Comprehensive Market Scan Reports - Улправда
Have Insiders Sold Arcus Biosciences Shares Recently? - simplywall.st
Squarepoint Ops LLC Boosts Stake in Arcus Biosciences, Inc. $RCUS - MarketBeat
Can Arcus Biosciences Inc. stock deliver sustainable ROEMarket Sentiment Report & Technical Confirmation Trade Alerts - Улправда
How higher bond yields impact Arcus Biosciences Inc. stockJuly 2025 Breakouts & Safe Entry Trade Signal Reports - ulpravda.ru
Is Arcus Biosciences Inc. stock attractive after correctionEarnings Growth Summary & Weekly Stock Performance Updates - Bölüm Sonu Canavarı
Market Outlook: Can Arcus Biosciences Inc. stock maintain operating marginsQuarterly Market Summary & Daily Entry Point Trade Alerts - DonanımHaber
Arcus Biosciences (NYSE:RCUS) Insider Richard Markus Sells 4,494 Shares - MarketBeat
Insider Selling: Arcus Biosciences (NYSE:RCUS) CAO Sells 4,343 Shares of Stock - MarketBeat
Carolyn Tang Sells 7,658 Shares of Arcus Biosciences (NYSE:RCUS) Stock - MarketBeat
Arcus Biosciences (NYSE:RCUS) President Sells $245,603.00 in Stock - MarketBeat
Robert Goeltz II Sells 6,702 Shares of Arcus Biosciences (NYSE:RCUS) Stock - MarketBeat
Arcus Biosciences (NYSE:RCUS) CEO Sells $633,360.36 in Stock - MarketBeat
Arcus Biosciences (NYSE:RCUS) General Counsel Sells $150,909.60 in Stock - MarketBeat
Arcus Biosciences amends loan agreement, extends maturity and updates terms - Investing.com Nigeria
Arcus Biosciences Insider Sold Shares Worth $466,870, According to a Recent SEC Filing - marketscreener.com
Arcus Biosciences Insider Sold Shares Worth $278,739, According to a Recent SEC Filing - marketscreener.com
Arcus Biosciences Insider Sold Shares Worth $318,496, According to a Recent SEC Filing - marketscreener.com
Arcus Biosciences Executives Sell Shares to Cover Tax Obligations - TradingView — Track All Markets
Officer Azoy Sells 4,343 ($96.6K) Of Arcus Biosciences Inc [RCUS] - TradingView — Track All Markets
[Form 4] Arcus Biosciences, Inc. Insider Trading Activity - Stock Titan
Arcus Biosciences Amends Loan Facility, Extends Maturity Terms - TipRanks
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Cancer-focused Arcus Biosciences to present at major health conference - Stock Titan
February 2026 Options Now Available For Arcus Biosciences (RCUS) - Nasdaq
This growth stock with 137% upside faces new challenge: Buy, hold or sell? - MSN
Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221 (NYSE:RCUS) - Seeking Alpha
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Arcus Biosciences Inc Azioni (RCUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):